These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30635299)

  • 1. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.
    Thompson A; Carroll K; A Inker L; Floege J; Perkovic V; Boyer-Suavet S; W Major R; I Schimpf J; Barratt J; Cattran DC; S Gillespie B; Kausz A; W Mercer A; Reich HN; H Rovin B; West M; Nachman PH
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):469-481. PubMed ID: 30635299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
    Inker LA; Heerspink HJL; Tighiouart H; Chaudhari J; Miao S; Diva U; Mercer A; Appel GB; Donadio JV; Floege J; Li PKT; Maes BD; Locatelli F; Praga M; Schena FP; Levey AS; Greene T
    Am J Kidney Dis; 2021 Sep; 78(3):340-349.e1. PubMed ID: 33775708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.
    Tang C; Chen P; Si FL; Lv JC; Shi SF; Zhou XJ; Liu LJ; Zhang H
    Am J Kidney Dis; 2024 Aug; 84(2):170-178.e1. PubMed ID: 38364955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
    Zhang L; Liu X; Pascoe EM; Badve SV; Boudville NC; Clayton PA; De Zoysa J; Hawley CM; Kanellis J; McDonald SP; Peh CA; Polkinghorne KR; Johnson DW
    Nephrology (Carlton); 2016 May; 21(5):387-96. PubMed ID: 26393772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
    Canney M; Barbour SJ; Zheng Y; Coppo R; Zhang H; Liu ZH; Matsuzaki K; Suzuki Y; Katafuchi R; Reich HN; Cattran D; ;
    J Am Soc Nephrol; 2021 Feb; 32(2):436-447. PubMed ID: 33514642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.
    Inker LA; Mondal H; Greene T; Masaschi T; Locatelli F; Schena FP; Katafuchi R; Appel GB; Maes BD; Li PK; Praga M; Del Vecchio L; Andrulli S; Manno C; Gutierrez E; Mercer A; Carroll KJ; Schmid CH; Levey AS
    Am J Kidney Dis; 2016 Sep; 68(3):392-401. PubMed ID: 27032886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population.
    Le W; Liang S; Hu Y; Deng K; Bao H; Zeng C; Liu Z
    Nephrol Dial Transplant; 2012 Apr; 27(4):1479-85. PubMed ID: 21965586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients.
    Pesce F; Diciolla M; Binetti G; Naso D; Ostuni VC; Di Noia T; Vågane AM; Bjørneklett R; Suzuki H; Tomino Y; Di Sciascio E; Schena FP
    Nephrol Dial Transplant; 2016 Jan; 31(1):80-6. PubMed ID: 26047632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgA nephropathy: an overview of drug treatments in clinical trials.
    Selvaskandan H; Gonzalez-Martin G; Barratt J; Cheung CK
    Expert Opin Investig Drugs; 2022 Dec; 31(12):1321-1338. PubMed ID: 36588457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.
    Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):947-955. PubMed ID: 27026518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic features aid in predicting risk for progression of IgA nephropathy.
    Walsh M; Sar A; Lee D; Yilmaz S; Benediktsson H; Manns B; Hemmelgarn B
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):425-30. PubMed ID: 20089495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.
    Donadio JV; Bergstralh EJ; Grande JP; Rademcher DM
    Nephrol Dial Transplant; 2002 Jul; 17(7):1197-203. PubMed ID: 12105241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient classification and outcome prediction in IgA nephropathy.
    Diciolla M; Binetti G; Di Noia T; Pesce F; Schena FP; Vågane AM; Bjørneklett R; Suzuki H; Tomino Y; Naso D
    Comput Biol Med; 2015 Nov; 66():278-86. PubMed ID: 26453758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria in the prognosis of IgA nephropathy.
    Aucella F; Netti GS; Piemontese M; Cincione IR; Infante B; Gesualdo L
    Minerva Urol Nefrol; 2009 Sep; 61(3):235-48. PubMed ID: 19773725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine, and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review.
    Palmer SC; Ruospo M; Teixeira-Pinto A; Craig JC; Macaskill P; Strippoli GFM
    Am J Kidney Dis; 2018 Dec; 72(6):779-789. PubMed ID: 30149958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin Markedly Decreased Proteinuria in a Patient With IgA Nephropathy.
    Aameish M; Jovanovic M; John MA; Baumstein D
    Cureus; 2021 Nov; 13(11):e19446. PubMed ID: 34912597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.